Delving into the Latest Updates on Noscapine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(−)-narcotine, (−)-α-narcotine, Narcosine

+ [12]

Target-

Mechanism-

Therapeutic Areas

Respiratory DiseasesNeoplasmsImmune System Diseases+ [1]

Active Indication

CoughChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma

Inactive Indication

Low Grade B-Cell Non-Hodgkin's Lymphoma

Originator Organization

Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.

Active Organization

Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.

Janssen Oncology, Inc.Qinghai Pharmaceutical Factory Co. Ltd.

Inactive Organization

University of Southern California

Drug Highest PhaseApproved

First Approval Date-

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC22H23NO7

InChIKeyAKNNEGZIBPJZJG-MSOLQXFVSA-N

CAS Registry128-62-1

Noscapine, a tetrahydroisoquinoline alkaloid, was first isolated from Papaver somniferum and identified by Rabiquet in 1817. It has been used as an anti-tussive agent since the mid-1950 s. After the discovery of its anti-mitotic potential, it was into the limelight once again. Due to its low toxicity, high bioactivity and oral administration, It was regarded as a formidable framework for subsequent modification and advancement in the pursuit of innovative chemotherapeutic agents. Up to now, the rational derivatives of the noscapine have been designed and the biological activities of these analogues have been extensively investigated. This review provides a comprehensive examination of the chemical characteristics of noscapine and its semi-synthetic derivatives up to the present, encompassing a concise investigation into the biological properties of these compounds and additionally a discussion about biosynthesis and total synthesis of noscapine is also provided. In summary, our aim is to contribute to a more thorough comprehension of this structure. It can be asserted that a promising future lies ahead for noscapine and its engineered derivatives as noteworthy candidates for pharmaceutical drugs.

19 Oct 2024·Experimental Aging Research

Behavioral and Neurological Effects of Edaravone and Noscapine in Albino Wistar Rats

Article

Author: Doshi, Gaurav Mahesh ; Hafizur Rehman, Mamsa Rumaiza ; Godad, Angel Pavalu

OBJECTIVEThe purpose of the study was to explore Edaravone and Noscapine in anAlCl3-induced Alzheimer's disease (AD) model.METHODSMorris Water Maze (MWM), Novel Object Recognition (NOR), andY-maze tests with TNF-α, IL-1, IL-6, amyloid-β, CAT, SOD and MDAlevels were performed, followed by brain histology.RESULTSOn the probe trial, the MWM demonstrated a decrease in escape latencyfollowed by an increase in the target quadrant. The NOR showeddiscrimination and recognition index scores and Y-maze, revealed arise in spontaneous alterations. TNF-α, IL-1, IL-6, amyloid-β, CATand MDA levels increased, while SOD levels dropped. The results werefound to be significant for combination full and half doses (***p <0.001, **p < 0.01). The treated group's histology ofbrain revealed mild neurodegeneration with hippocampal pyknoticnuclei.CONCLUSIONSThus, Edaravone and Noscapine can be used for thetreatment of AD. .

01 Oct 2024·Heliyon

Synthesis and in vitro study of surface-modified and anti-EGFR DNA aptamer -conjugated chitosan nanoparticles as a potential targeted drug delivery system

Article

Author: Rahmani Kheyrollahi, Maryam ; Mohammadnejad, Javad ; Eidi, Akram ; Jafary, Hanieh

Nowadays, finding effective approaches for cancer therapy is one of the significant issues related to human health all over the world. Hence, in this research, we designed and synthesized a novel targeted DDS based on surface-modified chitosan (CS) for the effective delivery of noscapine (NO). As the surface of CS nanoparticles was firstly modified with carboxyl groups and followed by covalent conjugation of DNA-aptamer (Ap) as targeting and receptor blocker agent. Secondly, NO, as a chemotherapeutic agent, was loaded into prepared nano-complex and synthetics were effectively characterized via various analytical devices, including FT-IR, 1H NMR, DLS, Zeta potential analyzer, TGA, TEM, and SEM to verify quality and quantity of synthetics. Drug loading was obtained about 25 % and sustained drug release was observed for nano-complex at different pHs. Then, the cell viability assay was performed on MCF-7 (as breast cancer cell) and HFF-1 (as normal cell) cell lines to investigate cancer cell inhibition potency of nano-complex. Cell viability of cancer cells was 19.84 ± 1.87 % (for C-CS-Ap-NO) and 75.43 ± 2.64 % (for C-CS-Ap) after 72 h of treatment with 400 nM concentration. These results have been confirming the excellent potency of synthesized novel nano-complex as practical DDS in cancer therapy.

100 Deals associated with Noscapine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01036	Noscapine	R05DA07	DB06174

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cough	CN	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	-
Cough	CN	Qinghai Pharmaceutical Factory Co. Ltd.	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Hodgkin Lymphoma	Phase 1	US	Janssen Oncology, Inc.	16 Nov 2005
Chronic Lymphocytic Leukemia	Phase 1	US	University of Southern California	01 Mar 2000
Low Grade B-Cell Non-Hodgkin's Lymphoma	Phase 1	US	University of Southern California	01 Mar 2000

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ERS2014	Not Applicable	Bronchial Spasm	-	Chloroquine	gdqugvbqso(wnygwwevbi) = ljefyfhubs jbbdjsbwsl (ruuyqsdkxu )	-	01 Sep 2014
				Noscapine	gdqugvbqso(wnygwwevbi) = ppiclpjooc jbbdjsbwsl (ruuyqsdkxu )
AACR2010	Not Applicable	Breast Cancer	-	Noscapine and Doxorubicin	nkualozkyz(altdrmgzxw) = swvkzifyvo qybljhtpdh (nlnwpujwnz )	-	15 Apr 2010
				MNCs	gsverpuqzj(eyecqlejuf) = uaxlcycbzv byqoozbxuo (qstswfrujl ) View more